Geode Capital Management
NKTR icon

Geode Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Geode Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.5M Buy
881,306
+534,511
+154% +$39.1M ﹤0.01% 1518
2026
Q1 		$25M Buy
346,795
+92,434
+36% +$5.26M ﹤0.01% 1878
2025
Q4 		$10.8M Buy
254,361
+29,125
+13% +$1.63M ﹤0.01% 2385
2025
Q3 		$12.8M Buy
225,236
+92,863
+70% +$3.07M ﹤0.01% 2265
2025
Q2 		$3.42M Sell
132,373
-134,902
-50% -$1.51M ﹤0.01% 2923
2025
Q1 		$2.73M Buy
267,275
+3,436
+1% +$44.9K ﹤0.01% 2932
2024
Q4 		$3.68M Sell
263,839
-367
-0.1% -$6.47K ﹤0.01% 2890
2024
Q3 		$5.15M Sell
264,206
-9,961
-4% -$190K ﹤0.01% 2743
2024
Q2 		$5.1M Buy
274,167
+137,295
+100% +$2.89M ﹤0.01% 2706
2024
Q1 		$1.92M Buy
136,872
+898
+0.7% +$9.4K ﹤0.01% 3127
2023
Q4 		$1.15M Buy
135,974
+5,617
+4% +$42.5K ﹤0.01% 3302
2023
Q3 		$1.16M Buy
130,357
+3,959
+3% +$38.1K ﹤0.01% 3260
2023
Q2 		$1.09M Sell
126,398
-108,140
-46% -$1.15M ﹤0.01% 3316
2023
Q1 		$2.47M Buy
234,538
+4,957
+2% +$150K ﹤0.01% 2942
2022
Q4 		$7.78M Buy
229,581
+7,848
+4% +$380K ﹤0.01% 2423
2022
Q3 		$10.6M Buy
221,733
+4,802
+2% +$286K ﹤0.01% 2202
2022
Q2 		$12.4M Buy
216,931
+53,367
+33% +$3.37M ﹤0.01% 2104
2022
Q1 		$13.2M Buy
163,564
+6,387
+4% +$945K ﹤0.01% 2157
2021
Q4 		$31.9M Sell
157,177
-211
-0.1% -$45.8K ﹤0.01% 1654
2021
Q3 		$42.4M Sell
157,388
-1,887
-1% -$454K 0.01% 1416
2021
Q2 		$41M Buy
159,275
+4,160
+3% +$1.15M 0.01% 1480
2021
Q1 		$46.5M Buy
155,115
+2,730
+2% +$850K 0.01% 1285
2020
Q4 		$38.9M Buy
152,385
+13,429
+10% +$3.47M 0.01% 1289
2020
Q3 		$34.6M Sell
138,956
-4,919
-3% -$1.55M 0.01% 1126
2020
Q2 		$50M Buy
143,875
+3,130
+2% +$977K 0.01% 896
2020
Q1 		$37.7M Buy
140,745
+4,769
+4% +$1.48M 0.01% 918
2019
Q4 		$44M Sell
135,976
-51,682
-28% -$15M 0.01% 1032
2019
Q3 		$51.2M Buy
187,658
+6,224
+3% +$2.28M 0.01% 872
2019
Q2 		$96.7M Buy
181,434
+21,562
+13% +$10.8M 0.02% 576
2019
Q1 		$80.4M Buy
159,872
+10,926
+7% +$6.47M 0.02% 627
2018
Q4 		$73.3M Buy
148,946
+343
+0.2% +$207K 0.02% 576
2018
Q3 		$136M Buy
148,603
+18,786
+14% +$16M 0.04% 442
2018
Q2 		$94.9M Sell
129,817
-6,340
-5% -$7.31M 0.03% 533
2018
Q1 		$217M Buy
136,157
+39,759
+41% +$51.2M 0.07% 276
2017
Q4 		$86.4M Buy
96,398
+930
+1% +$550K 0.03% 528
2017
Q3 		$34.4M Buy
95,468
+3,444
+4% +$1.08M 0.01% 876
2017
Q2 		$27M Buy
92,024
+2,684
+3% +$776K 0.01% 989
2017
Q1 		$31.5M Buy
89,340
+10,091
+13% +$2.27M 0.01% 860
2016
Q4 		$14.6M Buy
79,249
+12,319
+18% +$2.5M 0.01% 1321
2016
Q3 		$17.2M Buy
66,930
+874
+1% +$225K 0.01% 1101
2016
Q2 		$14.1M Buy
66,056
+737
+1% +$165K 0.01% 1175
2016
Q1 		$13.5K Buy
65,319
+4,807
+8% +$923K 0.01% 1173
2015
Q4 		$15.3M Buy
60,512
+2,377
+4% +$489K 0.01% 1069
2015
Q3 		$9.56M Buy
58,135
+2,007
+4% +$355K 0.01% 1374
2015
Q2 		$10.5M Buy
56,128
+1,844
+3% +$317K 0.01% 1390
2015
Q1 		$8.96M Buy
54,284
+4,396
+9% +$903K 0.01% 1470
2014
Q4 		$11.6M Buy
49,888
+805
+2% +$172K 0.01% 1207
2014
Q3 		$8.89M Buy
49,083
+561
+1% +$107K 0.01% 1356
2014
Q2 		$9.33M Buy
48,522
+1,895
+4% +$335K 0.01% 1350
2014
Q1 		$8.48M Buy
46,627
+8,185
+21% +$1.62M 0.01% 1369
2013
Q4 		$6.54M Buy
38,442
+3,902
+11% +$629K ﹤0.01% 1493
2013
Q3 		$5.41M Buy
34,540
+1,039
+3% +$192K ﹤0.01% 1504
2013
Q2 		$5.8M Buy
+33,501
New +$5.14M 0.01% 1300

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Geode Capital Management's NKTR Position: Q2 2026 in Review

Geode Capital Management increased its Nektar Therapeutics (NKTR) stake by 154% in Q2 2026, buying an estimated $39.1M and bringing the position to 881,306 shares worth $61.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1518.

Geode Capital Management first reported a position in NKTR in Q2 2013 and has held it in 53 quarters since. The position peaked at $217M in Q1 2018. 219 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Geode Capital Management held 881,306 shares of Nektar Therapeutics worth $61.5M as of Q2 2026.
  • Geode Capital Management bought 534,511 Nektar Therapeutics shares in Q2 2026, an estimated $39.1M.
  • Nektar Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1518 holding.
  • Geode Capital Management first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Geode Capital Management's Nektar Therapeutics position peaked at $217M in Q1 2018.
  • 219 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.